Breast cancer prognosis associated with oncometabolite accumulation

December 9, 2013

The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns, and breast cancer prognosis.

The authors identified a breast cancer subtype with high levels of 2-HG, and a district DNA methylation pattern that was associated with reduced survival.

This breast cancer subtype was common in African-American breast cancer patients, who as a group have a high prevalence of aggressive breast cancers.

This study indicates that evaluation of 2-HG along with DNA methylation may be a useful biomarker for diagnosis and prognosis

Explore further: Linking risk factors and disease origins in breast cancer

More information: MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis, J Clin Invest. DOI: 10.1172/JCI71180

Related Stories

Linking risk factors and disease origins in breast cancer

November 20, 2013

Researchers from the Geisel School of Medicine at Dartmouth have found that epigenetic changes to DNA are associated with aging in disease-free breast tissues and are further altered in breast tumors. Epigenetic changes describe ...

DNA methylation level is marker of breast cancer risk

May 11, 2012

(HealthDay) -- Women with high levels of white blood cell (WBC) DNA methylation at the ATM loci have a significantly increased risk of breast cancer, regardless of family history or menopausal status, according a study published ...

Recommended for you

Study: Colonoscopy after 75 may not be worth it

September 26, 2016

(HealthDay)—A colonoscopy can find and remove cancerous growths in the colon, but it may not provide much cancer prevention benefit after the age of 75, a new study suggests.

Research finds talc doesn't cause cancer; juries disagree

September 26, 2016

Two lawsuits ended in jury verdicts worth $127 million. Two others were tossed out by a judge who said there wasn't reliable evidence that the talc in Johnson & Johnson's iconic baby powder causes ovarian cancer. So who's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.